Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/96041
PIRA download icon_1.1View/Download Full Text
Title: Nanomedicine-boosting tumor immunogenicity for enhanced immunotherapy
Authors: Huang, J
Yang, B
Peng, Y
Huang, JS
Wong, SHD 
Bian, LM 
Zhu, KS
Shuai, XT
Han, SS
Issue Date: 21-May-2021
Source: Advanced functional materials, 21 May 2021, v. 31, no. 21, 2011171
Abstract: Immunotherapy has revolutionized oncology remarkably and gained great improvements in cancer therapy. However, tumor immunotherapy still encounters serious challenges, especially certain tumors barely respond to immunotherapy. The lack of immunogenicity and subsequent insufficient antitumor immune activation is a pivotal reason. Here, a general introduction and the strengthening strategies of immunogenicity of a tumor for enhanced immunotherapy are reviewed. Specifically, nanotechnology nowadays is playing important roles in increasing the antitumor efficacy of various treatments, including immunotherapy. This review highlights how nanomedicines integrating one or more anticancer therapeutic methods (e.g., cancer vaccines, chemotherapy, phototherapy, and radiotherapy) to increase the tumor immunogenicity for rousing T cell related immune responses and achieving inspiring antitumor efficacy. Given the sophisticated immune evasion mechanisms, rational designed nanodrugs with combinational formulations are summarized to improve therapeutic efficacy in synergistic ways. Nanoplatforms taking advantage of the distinct features of tumor tissue or tumor cell with stimuli-responsiveness and targeting functions are introduced to accelerate tumor accumulation of drugs successfully and greatly promote therapeutic efficacy with low-dose administration and programmed drug release. Finally, the related challenges and personal perspectives of nanomedicines for tumor immunotherapy are concluded.
Keywords: Combination therapy
Immunogenecity
Nanomedicine
Tumor immunotherapy
Publisher: Wiley-VCH
Journal: Advanced functional materials 
ISSN: 1616-301X
EISSN: 1616-3028
DOI: 10.1002/adfm.202011171
Rights: © 2021 Wiley-VCH GmbH
This is the peer reviewed version of the following article: Huang, J., Yang, B., Peng, Y., Huang, J., Wong, S. H. D., Bian, L., Zhu, K., Shuai, X., Han, S., Nanomedicine-Boosting Tumor Immunogenicity for Enhanced Immunotherapy. Adv. Funct. Mater. 2021, 31, 2011171, which has been published in final form at https://doi.org/10.1002/adfm.202011171. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
Appears in Collections:Journal/Magazine Article

Files in This Item:
File Description SizeFormat 
Huang_Nanomedicine_Boosting_Tumor.pdfPre-Published version3.15 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Final Accepted Manuscript
Access
View full-text via PolyU eLinks SFX Query
Show full item record

Page views

69
Last Week
0
Last month
Citations as of May 19, 2024

Downloads

273
Citations as of May 19, 2024

SCOPUSTM   
Citations

88
Citations as of May 16, 2024

WEB OF SCIENCETM
Citations

87
Citations as of May 16, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.